Where Will Regeneron Pharmaceuticals Inc (REGN) Stock Go Next After It Has Gained 1.56% in a Week?

Overall market sentiment has been high on Regeneron Pharmaceuticals Inc (REGN) stock lately. REGN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Regeneron Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on REGN!

See Full REGN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With REGN Stock Today?

Regeneron Pharmaceuticals Inc (REGN) stock is down -1.59% while the S&P 500 has risen 0.5% as of 3:13 PM on Friday, Dec 1. REGN is lower by -$13.06 from the previous closing price of $823.81 on volume of 266,792 shares. Over the past year the S&P 500 has gained 12.51% while REGN has risen 7.86%. REGN earned $35.05 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 23.14. To screen for more stocks like Regeneron Pharmaceuticals Inc click here.

More About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently. Click Here to get the full Stock Report for Regeneron Pharmaceuticals Inc stock.